Early diagnosis and clinical characterization of complete versus incomplete Kawasaki disease in children in Rui'an City: a retrospective study

Backgrounds: The aim of this study was to analyze the clinical characteristics of complete Kawasaki disease (CKD) and incomplete Kawasaki disease (IKD) in children in Rui’an City, with a view to providing a basis for early recognition of IKD by clinicians. Methods: 94 children with suspected Kawasaki disease (KD) admitted to our hospital between October 2017 and October 2023 were selected as the study subjects. Results: The duration of fever in the IKD group was significantly longer than that in the CKD group (p < 0.05), while the incidence of rash, fingertip changes, conjunctival congestion, and cervical lymph node enlargement were significantly lower than that in the CKD group (p < 0.05). In contrast to the CKD group, the IKD group exhibited significantly elevated levels of C-reactive protein (CRP), platelet count (PLT), N-terminal brain natriuretic peptide precursor (NT-proBNP) and albumin (ALB) (p < 0.05), whereas the level of alanine aminotransferase (ALT) was significantly lower (p < 0.05). In the IKD group, a greater percentage of children exhibited sinus tachycardia compared to the CKD group (p < 0.05). The incidence of coronary artery lesions (CAL) was significantly higher in the IKD group than in the CKD group (p < 0.05). There were 14 cases (15.91%) in the IKD group and 6 cases (6.38%) in the CKD group showed resistance to gammaglobulin treatment (χ2 = 4.217, p = 0.040). Conclusions: Children with IKD experienced prolonged fever duration, a notably reduced rate of positive clinical symptoms, and marked irregularities in lab parameters such as CRP, PLT, NT-proBNP and ALB, as well as a significantly higher incidence of CAL. A thorough examination incorporating data from various angles in clinical settings can provide valuable insights for diagnosing and treating pediatric patients with IKD in Rui’an City.

Complete Kawasaki disease; Incomplete Kawasaki disease; Clinical features; Rui’an City

[1] Wang H, Shimizu C, Bainto E, Hamilton S, Jackson HR, Estrada-Rivadeneyra D, et al. Subgroups of children with Kawasaki disease: a data-driven cluster analysis. The Lancet Child & Adolescent Health. 2023; 7: 697–707.

[2] Noval Rivas M, Arditi M. Kawasaki disease and multisystem inflammatory syndrome in children: common inflammatory pathways of two distinct diseases. Rheumatic Diseases Clinics of North America. 2023; 49: 647–659.

[3] Al Zubaidi A, Ghatasheh G, Karuppaswamy V, Narchi H. Epidemiology of Kawasaki disease, its incomplete form and outcomes: a single-institution experience in the United Arab Emirates. Cureus. 2023; 15: e51320.

[4] Jone PN, Tremoulet A, Choueiter N, Dominguez SR, Harahsheh AS, Mitani Y, et al. Update on diagnosis and management of Kawasaki disease: a scientific statement from the American Heart Association. Circulation. 2024; 150: e481–e500.

[5] Gorelik M, Chung SA, Ardalan K, Binstadt BA, Friedman K, Hayward K, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease. Arthritis Care & Research. 2022; 74: 538–548.

[6] Liu J, Yue Q, Qin S, Su D, Ye B, Pang Y. Risk factors and coronary artery outcomes of coronary artery aneurysms differing in size and emergence time in children with Kawasaki disease. Frontiers in Cardiovascular Medicine. 2022; 9: 969495.

[7] Sapountzi E, Kotanidou EP, Tsinopoulou VR, Kalinderi K, Fidani L, Giannopoulos A, et al. Kawasaki disease: an update on genetics and pathophysiology. Genetic Testing and Molecular Biomarkers. 2024; 28: 373–383.

[8] Jiao F, Pan Y, Du Z, Deng F, Yang X, Wang H, et al. Guideline for the diagnosis and treatment of incomplete Kawasaki disease in children in China. BMC Pediatrics. 2024; 24: 477.

[9] Cai WJ, Ding SG. Retrospective analysis of clinical characteristics and related influencing factors of Kawasaki disease. Medicine. 2022; 101: e32430.

[10] Li T, Feng J, Li N, Liu T. Correct identification of incomplete Kawasaki disease. Journal of International Medical Research. 2021; 49: 3000605211001712.

[11] Selmek K, Harding M. Kawasaki disease. Pediatrics in Review. 2024; 45: 425–427.

[12] Burney JA, Roberts SC, DeHaan LL, Shimizu C, Bainto EV, Newburger JW, et al. Epidemiological and clinical features of Kawasaki disease during the COVID-19 pandemic in the United States. JAMA Network Open. 2022; 5: e2217436.

[13] Wang L, Zeng X, Chen B. Clinical manifestations and risk factors of coronary artery lesions in children with Kawasaki disease. Medicine. 2023; 102: e34939.

[14] Banoo N, Bashir A, Tariq S, Radhakrishnan S, Abid S. Clinical profile of Kawasaki disease in children admitted at a tertiary care hospital of North India and their short-term follow-up. Annals of Pediatric Cardiology. 2021; 14: 459–464.

[15] Cannon L, Campbell MJ, Wu EY. Multisystemic inflammatory syndrome in children and Kawasaki disease: parallels in pathogenesis and treatment. Current Allergy and Asthma Reports. 2023; 23: 341–350.

[16] Shi L, Li J, Qie D, Hua X, Pan J, Shi X, et al. Clinical manifestations of Kawasaki disease in different age groups: retrospective data from Southwest China. Clinical Rheumatology. 2020; 39: 3027–3032.

[17] Tsoukas P, Yeung RSM. Kawasaki Disease—associated cytokine storm syndrome. Advances in Experimental Medicine and Biology. 2024; 1448: 365–383.

[18] Kolko N, Bhat YA, Al Mesned A, Al Qwaee A, Al Akhfash A, Alhobani M, et al. Comparison of demographic, clinical, and echocardiographic features between complete and incomplete, and early and late presenters of Kawasaki disease: a 10-year single-center experience. Cureus. 2023; 15: e45819.

[19] Shuai S, Zhang H, Zhang R, Tang M, Luo E, Yang Y, et al. Prediction of coronary artery lesions based on C-reactive protein levels in children with Kawasaki disease: a retrospective cohort study. Jornal de Pediatria. 2023; 99: 406–412.

[20] Noval Rivas M, Kocatürk B, Franklin BS, Arditi M. Platelets in Kawasaki disease: mediators of vascular inflammation. Nature Reviews Rheumatology. 2024; 20: 459–472.

[21] Kim SH, Hwang IJ, Cho YK. Platelet indices as diagnostic marker for Kawasaki disease. Chonnam Medical Journal. 2022; 58: 110–118.

[22] Wang JR, Zhao HZ, Chang LJ, Xu X, Gao Y, Li M, et al. Predictive value of monocyte to HDL-C ratio for coronary artery lesions and intravenous immunoglobulin resistance in Kawasaki disease. European Journal of Pediatrics. 2023; 182: 4399–4406.

[23] Gao W, Chen Z, Lu Y, Bai X, Chen M, Lu Y. Analysis of ultrasound coronary parameters and blood red cell distribution width and N-terminal pro-brain natriuretic peptide concentrations following coronary lesions in children with Kawasaki disease. British Journal of Hospital Medicine. 2024; 85: 1–10.

[24] Galeotti C, Bajolle F, Belot A, Biscardi S, Bosdure E, Bourrat E, et al. French national diagnostic and care protocol for Kawasaki disease. La Revue de MéDecine Interne. 2023; 44: 354–380.

[25] Bressieux-Degueldre S, Gradoux E, Di Bernardo S, Sekarski N. Complete and incomplete Kawasaki disease: clinical differences and coronary artery outcome from a national prospective surveillance study in Switzerland. Frontiers in Pediatrics. 2023; 11: 1137841.

[26] Rajasekaran K, Duraiyarasan S, Adefuye M, Manjunatha N, Ganduri V. Kawasaki disease and coronary artery involvement: a narrative review. Cureus. 2022; 14: e28358.